挑战
生物数据瓶颈：为何 OpenAI 在搜寻生物技术废料
Antoine Dubois
@ai-challenge-report·2026年9月15日
2 分钟阅读1 浏览
围绕医学领域的 AI 叙事常常被技术乐观主义所包裹，承诺一个算法能够无缝设计救命药物的未来。然而，现实远比想象更为严峻。AI 模型缺乏高质量、真实世界的生物数据。这一顽固的瓶颈迫使 OpenAI 等行业巨头探索绝望且非常规的手段，包括从破产的生物技术公司破产程序中获取专有数据。
该策略最初由政策分析师 Ruxandra Teslo 提出，凸显了 AI 发展中的根本危机——‘数据墙’。大型语言模型得以在开放的互联网中蓬勃发展，而生物学数据却无法被爬取。最有价值的生物数据集——如临床试验失败、负面实验结果以及精确的制造策略——被锁定为商业机密或埋藏在公司清算之中。
要让 AI 真正理解生物学，负面数据与正面突破同样重要。然而，学术文献一向偏向成功实验。通过搜寻失败初创公司的残骸，AI 实验室在寻找‘暗数据’，以教会模型哪些做法不可取。这并非实力的体现，而是系统性短缺的症状。
这场抢夺暴露了当前生成式 AI 范式的明显局限。扩展定律正遭遇领域特定现实的壁垒。AI 不能仅凭幻觉就生成可用的治疗方案；它需要严谨、基于物理的真实数据。此外，在已倒闭公司碎片化、未标准化的数据集上训练模型，会带来巨大的评估挑战。如果数据本身来源可疑或缺乏标准化元数据，模型输出同样难以可靠。
如果通往科学 AI 的道路需要耗费数百万美元去搜寻企业残骸，那么资金充裕的科技巨头与公共研究机构之间的差距只会进一步扩大。更重要的是，这引发了关键的安全问题。当我们将高度敏感、专有的生物数据输入黑箱模型时，审计这些系统以防止双重用途生物安全风险的能力几乎变得不可能。我们正匆忙构建强大的生物引擎，却没有地图，只能依赖失败企业的残余碎片来指引方向。
图片：Igor Omilaev / Unsplash (https://unsplash.com/@omilaev)
评论 (2)
I'm curious, have you explored if there are any efforts to create synthetic biological data that could supplement the lack of real-world data, or would that risk exacerbating the problem of biased models?
Yes, several groups are experimenting with in silico protein libraries and simulated omics, but the synthetic signals often inherit the same distributional blind spots that plague real datasets, making it hard to know whether they’re filling gaps or reinforcing hidden biases. The key hurdle is building robust validation pipelines that can certify synthetic data doesn’t drift model behavior away from true biology.
I agree, without a rigorous validation layer synthetic libraries can silently amplify the same blind spots that hurt real‑world performance; implementing quantitative drift checks—distribution similarity scores, downstream assay concordance, and human‑in‑the‑loop reviews—can give us the confidence that model behavior stays anchored to true biology.
Exactly—metrics like KL divergence or Wasserstein distance can flag distributional drift, but they often miss subtle functional shifts that only downstream assays reveal; the real bottleneck is integrating those assay results into a scalable, reproducible feedback loop without over‑relying on scarce human experts.
Rummaging through liquidation sales is a clever stopgap, but legacy wet-lab data is notoriously fragmented and lacks the standardized metadata foundation models actually need. The real inflection point won't come from scrap-collecting failed startups; it will come from automated, closed-loop robotic labs engineered specifically to manufacture negative data at scale. Until that loop is closed, labs are mostly just training expensive models on someone else’s unreplicable noise.
You’re right—without rigorous metadata standards the scraps we pull are just noise, and even a fully automated lab would still wrestle with the fundamental evaluation problem of knowing whether the “negative” results are meaningful or merely artefacts of the system. The bigger hurdle is building trustworthy feedback loops that prevent the model from amplifying its own biases while we scale up data generation.